ストックスクリーナーアプリを入手
4.06
4.10%
0.16
アフターアワーズ：
4.14
0.08
+1.97%
前日終値:
$3.90
開ける：
$3.88
24時間の取引高:
1.06M
Relative Volume:
1.30
時価総額：
$335.22M
収益：
$14.20M
当期純損益:
$-49.59M
株価収益率:
-4.8196
EPS:
-0.8424
ネットキャッシュフロー:
$-35.25M
1週間 パフォーマンス:
+4.37%
1か月 パフォーマンス:
-15.42%
6か月 パフォーマンス:
+100.99%
1年 パフォーマンス:
+339.58%
1日の値動き範囲:
$3.8704
$4.25
1週間の範囲:
$3.80
$4.25
52週間の値動き範囲:
$0.9011
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
Compare IRD vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.06 | 323.25M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-16 | 開始されました | Oppenheimer | Outperform |
| 2026-01-20 | 開始されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | B. Riley Securities | Buy |
| 2025-11-25 | 開始されました | Piper Sandler | Overweight |
| 2025-10-29 | 開始されました | Wedbush | Outperform |
| 2025-10-16 | 開始されました | Chardan Capital Markets | Buy |
| 2025-04-11 | 開始されました | Craig Hallum | Buy |
| 2024-11-13 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Opus Genetics Inc (IRD) 最新ニュース
IRD Reiterated by Citizens -- Price Target Maintained at $11.00 - GuruFocus
Citizens reiterates Opus Genetics stock rating on development strategy By Investing.com - Investing.com Canada
Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target - Insider Monkey
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Opus Genetics (NASDAQ: IRD) registers 2.68M shares for resale by investors - Stock Titan
IRD Initiates Coverage by Guggenheim -- Rating Set to Buy - GuruFocus
Guggenheim Initiates Opus Genetics at Buy With $16 Price Target - Moomoo
Guggenheim Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $16 - Moomoo
Opus Genetics: The Future Lies In The Success Of The AAV Delivery Platform (NASDAQ:IRD) - Seeking Alpha
IRD Q1 2026 Earnings: Significant Earnings Miss Amid Pre-Revenue Clinical Development StageBalance Sheet Strength - newsline.com
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts - marketscreener.com
Opus Genetics Slides Ahead of June Test - Bez Kabli
Opus Genetics touts retinal gene therapy pipeline, September BEST1 data catalyst - MSN
Opus Genetics Inc. (IRD) Q1 2026 Earnings: Steep EPS Miss and No Revenue, Yet Stock Climbs $3.81Estimate Dispersion - newsline.com
IRD News | OPUS GENETICS INC (NASDAQ:IRD) - ChartMill
Opus Genetics reports inducement grants under Nasdaq listing rule - marketscreener.com
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Gene therapy for blindness: Opus Genetics heads to Jefferies 2026 - Stock Titan
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst - inkl
Leerink Partners initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
IRD Initiates Coverage by Leerink Partners -- Rating 'Outperform' - GuruFocus
Leerink initiates Opus Genetics stock with outperform rating By Investing.com - Investing.com South Africa
Leerink Partners Initiates Opus Genetics(IRD.US) With Buy Rating, Announces Target Price $10 - Moomoo
Leerink initiates Opus Genetics stock with outperform rating - Investing.com
Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target - marketscreener.com
Foundation Fighting Blindness Retinal Degeneration Fund Sells 1, - GuruFocus
Foundation fighting blindness fund sells $7.4m of Opus Genetics (IRD) stock - Investing.com Nigeria
Opus Genetics (IRD) investor files exit 13D after stake falls under 5% - Stock Titan
Foundation Fighting Blindness fund trims Opus Genetics (IRD) stake with 1.7M-share sale - Stock Titan
Opus Genetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
IRD: Gene therapy pipeline advances with pivotal data and regulatory milestones expected in 2024 - TradingView
Lifesci Capital Predicts Lower Earnings for Opus Genetics - MarketBeat
Opus Genetics, Inc. (IRD) reports Q1 loss, misses revenue estimates - MSN
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - MarketBeat
Nantahala Capital (IRD) reports 4.84M shares; 3.16M exercisable within 60 days - Stock Titan
Perceptive (IRD) group holds 9.99% of Opus Genetics; warrants capped by limit - Stock Titan
Caligan Partners reports 8.5% stake in Opus Genetics (IRD) - Stock Titan
HC Wainwright Lifts Earnings Estimates for Opus Genetics - MarketBeat
Balyasny holds 5.11M shares in Opus Genetics (NASDAQ: IRD), includes warrants - Stock Titan
Cantor Fitzgerald Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Opus Genetics (NASDAQ:IRD) Stock Rating Lowered by Zacks Research - MarketBeat
Opus Genetics (IRD) Projected to Post Quarterly Earnings on Thursday - MarketBeat
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $8 to $11 - Moomoo
IRD Maintained by Citizens -- Price Target Lowered to $11.00 - GuruFocus
Opus Genetics Inc (IRD) 財務データ
収益
当期純利益
現金流量
EPS
Opus Genetics Inc (IRD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Apr 23 '26 |
Sale |
5.24 |
7,470 |
39,121 |
711,535 |
| SCHACHLE JOSEPH K | Chief Operating Officer |
Apr 23 '26 |
Sale |
5.22 |
4,697 |
24,519 |
296,084 |
| Zaremba Rabourn Amy | Head of Fin. Quality Assurance |
Apr 23 '26 |
Sale |
5.20 |
1,641 |
8,540 |
188,671 |
| Magrath George | Chief Executive Officer |
Apr 23 '26 |
Sale |
5.22 |
9,511 |
49,647 |
1,741,344 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. |
Apr 23 '26 |
Sale |
5.19 |
7,542 |
39,156 |
509,233 |
| Gagnon Robert E. | Chief Financial Officer |
Apr 23 '26 |
Sale |
5.18 |
7,842 |
40,658 |
592,158 |
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):